Puma Biotechnology (PBYI) Non-Current Assets (2011 - 2026)
Puma Biotechnology's (PBYI) quarterly Non-Current Assets came in at $50.4 million in Q1 2026, down 20.78% YoY from $63.7 million in Q1 2025, and down 5.92% on a QoQ basis from $53.6 million in Q4 2025.
Puma Biotechnology (PBYI) Non-Current Assets (2011 - 2026) Analysis & Trends
Puma Biotechnology (PBYI) has 16 years of Non-Current Assets data on file, last reported at $50.4 million in Q1 2026.
- Quarterly Non-Current Assets fell 20.78% year-over-year to $50.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $221.7 million (down 14.91% YoY) and the FY2025 annual result came in at $53.6 million, down 18.36% from the prior year.
- Non-Current Assets fell to $50.4 million in Q1 2026, from $53.6 million in the prior quarter.
- In the past five years, Non-Current Assets ranged from a high of $87.8 million in Q4 2022 to a low of $50.4 million in Q1 2026.
- A 5-year average of $70.5 million and a median of $71.1 million in 2024 frame the typical range for Non-Current Assets.
- Annual changes were most pronounced in 2023 — Non-Current Assets climbed 3.24% — and 2026, when it decreased 20.78%.
- Tracing PBYI's Non-Current Assets over 5 years: stood at $87.8 million in 2022, then retreated by 15.31% to $74.3 million in 2023, then slipped by 11.66% to $65.7 million in 2024, then dropped by 18.36% to $53.6 million in 2025, then retreated by 5.92% to $50.4 million in 2026.
- The last three Non-Current Assets figures came in at $50.4 million (Q1 2026), $53.6 million (Q4 2025), and $59.3 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.96 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 294.93 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.96 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.76 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 18.06 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 938.60 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 468.65 Mn |
| 10 | Puma Biotechnology | 451.24 Mn | 357.33 Mn | 44.03 Mn | 47.66 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 47.66 Mn |
| Mar 31, 2026 | 50.44 Mn |
| Dec 31, 2025 | 53.62 Mn |
| Sep 30, 2025 | 59.28 Mn |
| Jun 30, 2025 | 58.34 Mn |
| Mar 31, 2025 | 63.67 Mn |
| Dec 31, 2024 | 65.68 Mn |
| Sep 30, 2024 | 63.90 Mn |
| Jun 30, 2024 | 67.28 Mn |
| Mar 31, 2024 | 71.12 Mn |
| Dec 31, 2023 | 74.34 Mn |
| Sep 30, 2023 | 78.25 Mn |
| Jun 30, 2023 | 81.94 Mn |
| Mar 31, 2023 | 84.50 Mn |
| Dec 31, 2022 | 87.78 Mn |
| Sep 30, 2022 | 76.42 Mn |
| Jun 30, 2022 | 79.37 Mn |
| Mar 31, 2022 | 83.12 Mn |
| Dec 31, 2021 | 86.56 Mn |
| Sep 30, 2021 | 89.36 Mn |